In late 2017, the Food and Drug Administration approved the first so-called smart pill, ushering in a new era of medical care. The inaugural effort involved embedding a sensor in Abilify, an old drug for treating schizophrenia and bipolar disorder, which can make it easier to track whether patients take their medicine, an especially thorny issue for people suffering from mental illness.

But in a new study, several researchers claim the regulatory endorsement was misguided.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • It’s not really evergreening when the same active ingredient is available in generic form without the tech piece. They don’t have a study so can’t claim improved adherence, though it is implicit in the concept of the technology.
    I suspect this isn’t doing much Rx-wise, but it’s still interesting technology that could be helpful in future applications. I do think schizophrenia is the worst place to begin, unless we’re talking about legally enforced administration, which I believe is rare and is definitely controversial.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy